Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences